Study with Reslizumab in Patients With Severe Eosinophilic Asthma

Study Title
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Teva Identifier
C38072-AS-30066 | 2016-004661-23
ClinicalTrials.gov Identifier
NCT03052725
Study Status
Terminated
Trial Condition(s)
Eosinophils, Asthma
Interventions
Drug: reslizumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial



Key Participation Requirements

Gender
Female, Male
Age Range
12 Years and older
Trial Duration
March 10, 2017 - February 22, 2018
Phase
Phase 3

Study Type

Interventional